title: Is on-demand treatment effective in patients with severe haemophilia?
abstract: On-demand therapy enables stopping haemorrhages rapidly, reducing joint pain and restoring joint mobility, but does not prevent the beginning and subsequent development of haemophilic arthropathy. The main objective of this study was to identify the clinical and orthopaedic status of severe haemophilic patients with bleeding phenotype receiving on-demand treatment in Spain. We conducted an epidemiological, observational, retrospective study, recruiting 167 patients from 36 centres (92% of them with haemophilia A), median age at enrolment of 35 years. Forty per cent of the patients received a combination of on-demand and short-term prophylaxis regimen; the rest was under on-demand treatment. One hundred and forty-five patients (87%) reported at least one bleeding episode and 22 (13%) of the biologically severe patients had no bleeding phenotype. Seventy-one per cent of the studied population presented established haemophilic arthropathy, reaching 80% if we exclude patients without bleeding phenotype. Forty-three per cent of these patients had one or two joints affected, 28% of them had three or four affected joints, 20% reported five or six affected joints and 9% more than six injured joints. An increase in established haemophilic arthropathy with age was observed. Forty-six patients underwent orthopaedic surgery at least once. These data show that on-demand therapy is not effective in preventing the development of haemophilic arthropathy in severe haemophilic population with bleeding phenotype. Therefore, we suggest that the optimal treatment in these patients should be based on prophylaxis. We recommend analysing the reasons for ending prophylaxis, in case its reinstatement should be necessary.
authors.affiliation: Haemostasis and Thrombosis Unit, University and Polytechnic Hospital La Fe, Valencia. aznar_jan@gva.es
authors.forename: J A
authors.initials: JA
authors.lastname: Aznar
authors.forename: A
authors.initials: A
authors.lastname: Marco
authors.forename: V
authors.initials: V
authors.lastname: Jiménez-Yuste
authors.forename: E
authors.initials: E
authors.lastname: Fernández-Fontecha
authors.forename: R
authors.initials: R
authors.lastname: Pérez
authors.forename: I
authors.initials: I
authors.lastname: Soto
authors.forename: R
authors.initials: R
authors.lastname: Parra
authors.forename: M
authors.initials: M
authors.lastname: Moreno
authors.forename: M E
authors.initials: ME
authors.lastname: Mingot
authors.forename: A
authors.initials: A
authors.lastname: Moret
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D005164:Factor IX / Q000008:administration & dosage; D005169:Factor VIII / Q000008:administration & dosage; D006395:Hemarthrosis / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control / Q000628:therapy; D006467:Hemophilia A / Q000150:complications / Q000453:epidemiology / Q000628:therapy*; D002836:Hemophilia B / Q000150:complications / Q000453:epidemiology / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013030:Spain / Q000453:epidemiology; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D005169:Factor VIII; D005164:Factor IX